<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272087</url>
  </required_header>
  <id_info>
    <org_study_id>Resp-REPEAT-SIRE-2</org_study_id>
    <nct_id>NCT03272087</nct_id>
  </id_info>
  <brief_title>Rational Approach to a Unilateral Pleural Effusion</brief_title>
  <acronym>REPEAT</acronym>
  <official_title>Rational Approach to Unilateral Pleural Effusion in Patients Suspected of Malignancy. Efficacy, Pain, Quality of Life, and Economy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent unilateral, non-infectious pleural exudate is suspicious for primary or secondary
      pleural malignancy. Both conditions are associated with 5-year survival of 10%. Work-up is
      difficult, as the pleural surface is large and &lt;33% of pleural malignancies shed malignant
      cells to the pleural fluid. Even so, additional tissue biopsies are needed for establishing
      mutation status for targeted therapies.

      Optimal imaging to guide tissue sampling is pivotal. PET-CT has higher sensitivity than
      conventional CT for detecting malignant lesions &gt;10mm. However, no randomised trial has
      investigated differences in diagnostic accuracy, time-to-diagnosis, or economics. Falsely
      PET-positive lesions in e.g. colon, however, lead to more derived tests than do CT alone.

      Gold standard for pleural tissue sampling is the surgical (VATS) thoracoscopy, allowing
      direct visual guiding of tissue sampling from all pleural surfaces. Yet, globally the medical
      (pleuroscopy) thoracoscopy is more widely used: cheaper, outpatient procedure, but allows
      only sampling from the parietal pleura. To date, no randomised studies have compared medical
      and surgical thoracoscopy concerning diagnostic hit rates, adverse events, or economics.

      Investigators will perform two randomized studies to investigate whether

        1. PET/CT is comparable to CT alone

        2. VATS is comparable to pleuroscopy concerning hit rate, total investigations performed,
           time-to-diagnosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients diagnosed with cancer</measure>
    <time_frame>2 years</time_frame>
    <description>(cancer = an unequivocal diagnosis of neoplastic disease; no cancer = clinically benign cause, and improved imaging at 6 month control).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>Questionnaire developed to assess the quality of life of cancer patients, QLQC 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs</measure>
    <time_frame>2 years</time_frame>
    <description>calculated as costs patient-related, procedure-related, and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>2 years</time_frame>
    <description>VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>A standardised instrument for use as a measure of health outcome, EuroQol EQ-5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pleuroscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VATS (thoracoscopy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thoracoscopy</intervention_name>
    <description>50 % of patients will have performed af medical thoracoscopy (pleuroscopy)</description>
    <arm_group_label>Pleuroscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VATS (thoracoscopy)</intervention_name>
    <description>50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy</description>
    <arm_group_label>VATS (thoracoscopy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with recurrent pleural effusion of unknown origin after a first pleural tap
             according to BTS guidelines.

          2. Indication for thoracoscopy according to BTS guidelines.

          3. Patients accept further investigation according to Danish and BTS guidelines.

          4. Have received oral and written consent and agreed.

          5. At the time of inclusion, above 18 years of age.

        Exclusion Criteria:

          1. Female patients: pregnancy or breastfeeding.

          2. Lack of language comprehension.

          3. Legally incompetent patients.

          4. Life expectancy less than 3 month.

          5. Contraindications to pleural tissue sampling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uffe Boedtger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Syddansk Universitet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon B Reuter, MD</last_name>
    <email>sire@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uffe Boedtger, MD, PhD</last_name>
    <email>ubt@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon B Reuter, MD</last_name>
      <email>sire@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Simon B Reuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Naestved Hospital</investigator_affiliation>
    <investigator_full_name>Simon Reuter</investigator_full_name>
    <investigator_title>Ph.d.-Student</investigator_title>
  </responsible_party>
  <keyword>Thoracoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

